Page 19 - 《中国药房》2026年7期

patients’ preferences for disease-modifying therapy at- [18] TAN S，WANG Y，TANG Y，et al. Societal preferences
tributes in multiple sclerosis[J]. Neurodegener Dis Manag， for funding orphan drugs in China：an application of the
2020，10（6）：369-382. discrete choice experiment method[J]. Front Public
[ 9 ] RIDE J，GORANITIS I，MENG Y，et al. A reporting Health，2022，10：1005453.
checklist for discrete choice experiments in health：the [19] 聂智峰，田夏，汪阳，等. 药品临床综合评价中MCDA赋
DIRECT checklist[J]. Pharmacoeconomics，2024，42 权方法比较[J]. 世界临床药物，2023，44（5）：437-444.
（10）：1161-1175. [20] FRIEDEL J E，FOREMAN A M，WIRTH O. An introduc‐
[10] BRIDGES J F P，HAUBER A B，MARSHALL D，et al. tion to “discrete choice experiments” for behavior analysts
Conjoint analysis applications in health：a checklist：a [J]. Behav Process，2022，198：104628.
report of the ISPOR good research practices for conjoint [21] 王珺琦，殷悦，唐文熙. 医保准入视角下罕见病用药经济
analysis task force[J]. Value Health，2011，14（4）： 价值评估的难点、方法与建议[J]. 卫生经济研究，2024，
403-413. 41（9）：58-61.
[11] MENTZAKIS E，STEFANOWSKA P，HURLEY J. A dis‐ [22] 曾淑金，吴良淼，翁开源. 多层次视角下国内外罕见病用
crete choice experiment investigating preferences for fun- 药保障支持体系研究[J]. 医学与社会，2023，36（3）：
ding drugs used to treat orphan diseases：an exploratory 30-35.
study[J]. Health Econ Policy Law，2011，6（3）：405-433. [23] GODMAN B，BUCSICS A，VELLA BONANNO P，et al.
[12] MOREL T，AYMÉ S，CASSIMAN D，et al. Quantifying Barriers for access to new medicines：searching for the
benefit-risk preferences for new medicines in rare disease balance between rising costs and limited budgets[J]. Front
patients and caregivers[J]. Orphanet J Rare Dis，2016， Public Health，2018，6：328.
11（1）：70. [24] CHEN H，XIANG Y，TANG X，et al. Establishment of a
[13] BOURKE S M，PLUMPTON C O，HUGHES D A. Soci‐ value assessment framework for orphan medicinal prod‐
etal preferences for funding orphan drugs in the United ucts in China[J]. Orphanet J Rare Dis，2024，19（1）：390.
Kingdom：an application of person trade-off and discrete [25] 韩屹，谷聪玲，宣建伟. 天津市A型血友病患者的疾病负
choice experiment methods[J]. Value Health，2018，21 担[J]. 中国药物经济学，2022，17（12）：18-22.
（5）：538-546. [26] CHAMBERS J D，SILVER M C，BERKLEIN F C，et al.
[14] LÓPEZ-BASTIDA J，RAMOS-GOÑI J M，ARANDA- Orphan drugs offer larger health gains but less favorable
RENEO I，et al. Using a stated preference discrete choice cost-effectiveness than non-orphan drugs[J]. J Gen Intern
experiment to assess societal value from the perspective Med，2020，35（9）：2629-2636.
of decision-makers in Europe. Does it work for rare [27] ZHANG X，DAI L，LONG Y，et al. Healthcare costs for
diseases? [J]. Health Policy，2019，123（2）：152-158. patients with rare diseases：evidence from China[J]. Int J
[15] LÓPEZ-BASTIDA J，RAMOS-GOÑI J M，ARANDA- Health Plann Manage，2024，39（1）：48-61.
RENEO I，et al. Using a stated preference discrete choice [28] ZHANG X，ZHOU T，ZHOU J，et al. Budget impact
experiment to assess societal value from the perspective of analysis of high-priced orphan medicinal products
patients with rare diseases in Italy[J]. Orphanet J Rare intended for the treatment of rare diseases in China：
Dis，2019，14（1）：154. evidence from a densely populated metropolis of Chengdu
[16] TOUMI M，MILLIER A，CRISTEAU O，et al. Social [J]. BMC Health Serv Res，2024，24（1）：1123.
preferences for orphan drugs：a discrete choice experiment [29] DABBOUS O，CHACHOUA L，ABALLÉA S，et al. Valu‐
among the French general population[J]. Front Med ation of treatments for rare diseases：a systematic litera‐
（Lausanne），2020，7：323. ture review of societal preference studies[J]. Adv Ther，
[17] DE ANDRÉS-NOGALES F，CRUZ E，CALLEJA M Á， 2023，40（2）：393-424.
et al. A multi-stakeholder multicriteria decision analysis （收稿日期：2025-10-28 修回日期：2026-03-03）
for the reimbursement of orphan drugs （FinMHU-MCDA （编辑：刘明伟）
study）[J]. Orphanet J Rare Dis，2021，16（1）：186.

中国药房 2026年第37卷第7期 China Pharmacy 2026 Vol. 37 No. 7 · 841 ·